96 Tests PN: B411185


45x Ab-conjugated beads (S5P7 - NHP RANTES Ab-bead). PN: B411185A. One vial containing 100 µL of anti-human RANTES conjugated to AimPlex Bead S5P7.

25x Biotin-detection Ab (NHP RANTES Biotin-dAb). PN: B411185B. One vial containing 100 µL of biotinylated anti-human RANTES.

Lyophilized Standard Mix-NHP Group 1 Panel B. PN: HG10011. One vial containing lyophilized recombinant Eotaxin, IL-1β, IL-1RA, IL-8, IL-12p70, IL-22, IP-10, MCP-1, MCP-3, and RANTES. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

Application: Optimal antibody pair and antigen standard for assaying NHP RANTES.  Can be multiplexed with other analytes in NHP Group 1.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: <10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in NHP Group 1: Negligible

  • Sample volume: 15 µL/test


RANTES/CCL5 is Regulated on Activation Normal T-cell Expressed and Secreted (Accession Q8HYQ1), a cytokine of the CC subfamily secreted by normal T-cells, as its name suggests. RANTES acts as a recruiter of leukocytes for inflammatory sites. In conjunction with IL-2 and IFN-γ, RANTES induces proliferation and activation of NK cells to form CHAK (CC Chemokine Activated Killer) cells. It is one of the most potent HIV-1 cytokine inhibitors.

It is suggested that RANTES plays a role in allograft rejection, as it has been detected within mononuclear cells and renal tubular epithelium. Diseases associated with RANTES include African Tick-bite fever, Kawasaki disease, glomerulonephritis. RANTES engineering by use of Lactobacillus jensenii may serve in development of effective microbicides for prevention of HIV.


  1. Krensky, AM. Biology of the Chemokine RANTES. Springer-Verlag, 1995.

  2. Donlon TA, Krensky AM, Wallace MR, Collins FS, Lovett M, Clayberger C). "Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11.2-q12". Genomics 1990;6 (3): 548–53. doi:10.1016/0888-7543(90)90485-D. PMID 1691736.

  3. Maghazachi AA, Al-Aoukaty A, Schall TJ. "CC chemokines induce the generation of killer cells from CD56+ cells". Eur. J. Immunol. 1996;26 (2): 315–9. doi:10.1002/eji.1830260207. PMID 8617297.

  4. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM "A human T cell-specific molecule is a member of a new gene family". J. Immunol. 1988;141 (3): 1018–25. PMID 2456327.

  5. Pattison JM, Nelson PJ, von Leuttichau I, Krensky AM, Huie P, Farshid G, Sibley RK. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. The Lancet. 1994; 343(8891): 209-211.